Investor Home

Investor Home

Corporate Profile

Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.

Lefamulin

Nabriva’s lead pleuromutilin product candidate, lefamulin, is being studied in two global, registrational Phase 3 clinical trials for the treatment of moderate to severe ... More >>

Recent Newsmore >
03/27/17
Nabriva Therapeutics to Present at the Needham and Company 16th Annual Healthcare Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., March 27, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Needham and Company 16th Annual Hea... 
03/24/17
Nabriva Therapeutics Provides Business and Development Update and Reports 2016 Financial Results
VIENNA, Austria and KING OF PRUSSIA, Pa., March 24, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today provided a business and clinical development update and reported its financial results for the year ended December 31, 2016. “For the last 12 months, we have been executing o... 
02/27/17
Nabriva Therapeutics to Present at the Cowen and Company 37th Annual Healthcare Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Cowen and Company 37th Annual Health... 
Upcoming Eventsmore >
DateTitleRemind
Me
Prior to
Event
04/05/17 2:20 p.m. ET
Nabriva Therapeutics at Needham and Company Annual Healthcare Conference
days
Enter your e-mail address 
Data provided by Nasdaq. Minimum 15 minutes delayed.